{
  "id": 16942017,
  "title": "Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer",
  "url": "https://urgent.news/2026/10/28/another-win-for-novel-drug-this-time-in-egfr-mutated-lung-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T19:03:01.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/esmo/123631"
  },
  "original_language": "en",
  "account": null,
  "summary": "A phase III trial conducted in China has shown promising results for izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate, in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who had progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). The trial, known as PANKU-Lung01, demonstrated that izabren nearly doubled progression-free survival (PFS) compared to chemotherapy, with a median PFS of 11.1 months versus 5.7 months. The benefit was observed across all prespecified subgroups, and confirmed objective responses were seen in 60.2% of patients receiving izabren versus 34.5% of those receiving chemotherapy. While overall survival data were still immature, the interim estimate favored izabren. The results suggest that izabren could be a promising new treatment option for EGFR-mutant NSCLC patients with EGFR TKI resistance, supporting its potential as a novel therapy in this patient population.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}